The ETA-ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor.

IF 3.5 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM European Thyroid Journal Pub Date : 2024-02-01 DOI:10.1530/ETJ-23-0244
Rodrigo Moreno-Reyes, Ulla Feldt-Rasmussen, Agnieszka Piekiełko-Witkowska, Adriana Gaspar da Rocha, Corin Badiu, Josef Koehrle, Leonidas Duntas
{"title":"The ETA-ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor.","authors":"Rodrigo Moreno-Reyes, Ulla Feldt-Rasmussen, Agnieszka Piekiełko-Witkowska, Adriana Gaspar da Rocha, Corin Badiu, Josef Koehrle, Leonidas Duntas","doi":"10.1530/ETJ-23-0244","DOIUrl":null,"url":null,"abstract":"<p><p>In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). \"We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g., hand disinfectants, disinfection of animals' teats/udder, embalming fluids before cremation, etc.) that contain molecular iodine (I2), entirely neglecting [see the 2013 ECHA Regulation (EU) n°528/2012 describing iodine as being of \"great importance for human health\". Clearly, the current sweeping and erroneous classification of \"iodine\" as an endocrine disruptor is ill-advised. We moreover call upon the scientific and medical community at large to use the accurate scientific nomenclature, i.e., iodide or iodate instead of \"iodine\" when referring to iodized salts and food prepared there with. Drugs, diagnostic agents, and synthetic chemicals containing the element iodine in the form of covalent bonds must be correctly labelled ''iodinated'', if possible, using each time their distinctive and accurate chemical or pharmacological name.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959048/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Thyroid Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/ETJ-23-0244","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

In 2022, the European Chemicals Agency (ECHA) made a statement concluding that iodine is an endocrine disruptor (ED). "We stress the fact that the ECHA opinion ECHA/BPC/357/2022 is based on their misguidedly zooming in on exclusively the biocidal products (e.g., hand disinfectants, disinfection of animals' teats/udder, embalming fluids before cremation, etc.) that contain molecular iodine (I2), entirely neglecting [see the 2013 ECHA Regulation (EU) n°528/2012 describing iodine as being of "great importance for human health". Clearly, the current sweeping and erroneous classification of "iodine" as an endocrine disruptor is ill-advised. We moreover call upon the scientific and medical community at large to use the accurate scientific nomenclature, i.e., iodide or iodate instead of "iodine" when referring to iodized salts and food prepared there with. Drugs, diagnostic agents, and synthetic chemicals containing the element iodine in the form of covalent bonds must be correctly labelled ''iodinated'', if possible, using each time their distinctive and accurate chemical or pharmacological name.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ETA-ESE 就欧洲化学品管理局关于碘作为内分泌干扰物的意见发表声明。
2022 年,欧洲化学品管理局(ECHA)发表声明,认定碘是一种内分泌干扰物(ED)。"我们强调,欧洲化学品管理局的意见ECHA/BPC/357/2022是基于他们误导性地专门放大含有分子碘(I2)的杀菌剂产品(如手部消毒剂、动物乳头/乳房消毒剂、火化前的防腐液等),完全忽视了[参见2013年欧洲化学品管理局条例(欧盟)n°528/2012,该条例将碘描述为 "对人类健康极为重要"。显然,目前一概将 "碘 "归类为内分泌干扰物的错误做法是不明智的。此外,我们呼吁广大科学界和医学界在提及碘盐和用碘盐制作的食品时,使用准确的科学术语,即碘化物或碘酸盐,而不是 "碘"。以共价键形式含有碘元素的药物、诊断剂和合成化学品必须正确标注 "碘化",如有可能,每次都应使用其独特而准确的化学或药理学名称。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Thyroid Journal
European Thyroid Journal Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
6.70
自引率
2.10%
发文量
156
期刊介绍: The ''European Thyroid Journal'' publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.
期刊最新文献
Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. Toward a treatment for thyroid hormone transporter MCT8 deficiency - achievements and challenges. Effects of iodine contrast media on thyroid function - a prospective study. Thyrotoxic periodic paralysis - a retrospective study from Southern India. Graves' hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1